Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

NOVO NORDISK A/S (NOVO.B)

167
 SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Copenhagen Stock Exchange
09/11/2014 09/12/2014 09/15/2014 09/16/2014 09/17/2014 Date
266.9 274 275.4 272.8 277.3 Last
2813390 5414738 2849222 2359220 2459975 Volume
+0.76% +2.66% +0.51% -0.94% +1.65% Change
Company
Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of... 
Sector
Pharmaceuticals
Calendar
09/19Presentation
Surperformance© rating of Novo Nordisk A/S
Trading Rating : Investor Rating :
More about the company
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO.B | DK0060534915 | 4-Traders
Full-screen chart
Financials ( DKK)
Sales 2014 88 082 M
EBIT 2014 33 517 M
Net income 2014 26 362 M
Finance 2014 7 285 M
Yield 2014 1,71%
Sales 2015 96 516 M
EBIT 2015 37 842 M
Net income 2015 29 496 M
Finance 2015 10 766 M
Yield 2015 1,96%
PER 2014 27,63
PER 2015 24,21
EV / Sales 2014 6,57x
EV / Sales 2015 5,96x
Capitalization 585 814 M
More Financials
Latest news on NOVO NORDISK A/S
1d ago NOVO NORDISK A/S : New Peptides and Proteins Study Results Reported from Novo No..
1d ago NOVO NORDISK A/S : Saxenda® for the treatment of obesity receives positive 14-1 ..
2d ago NOVO NORDISK A/S : New data show long-term efficacy and safety of Tresiba® in ch..
3d ago NOVO NORDISK A/S : Share repurchase programme
3d ago NOVO NORDISK A/S : Novo Nordisk A/S - Share repurchase programme
7d ago NOVO NORDISK A/S : Saxenda(R) for the treatment of obesity receives positive 14-..
7d ago NOVO NORDISK A/S : Saxenda® for the treatment of obesity receives positive 14-1 ..
7d ago NOVO NORDISK A/S : FDA panel backs Novo Nordisk injection for obesity
7d ago NOVO NORDISK A/S : MEDIA ALERT: Denmark's Crown Prince Couple Helps Mark 90 Year..
09/10 NOVO NORDISK A/S : "Conjugated Factor Viii Molecules" in Patent Application Appr..
09/10 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
09/09 NOVO NORDISK A/S : FDA posts briefing materials prior to Advisory Committee meet..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
Novo Nordisk A_S : Income Statement Evolution
More Financials
EPS Revisions
Novo Nordisk A_S : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF